SAB Biotherapeutics Inc. Common Stock SABS · Stock Open SAB Biotherapeutics Inc. Common Stock in new tab
Analyst price targets
Recent rating changes, newest first
SAB Biotherapeutics Inc. Common Stock Analysis (SABS)
Is SAB Biotherapeutics Inc. Common Stock a good investment? SAB Biotherapeutics Inc. Common Stock (SABS) is currently trading at 2.55 USD. Market analysts have a consensus price target of 11.64 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 12.75. This relatively low multiple may signal that SAB Biotherapeutics Inc. Common Stock is undervalued compared to historical market norms.
Earnings Schedule: SAB Biotherapeutics Inc. Common Stock is expected to release its next earnings report on Nov. 13, 2026. The market consensus estimate for Forward EPS is -0.95.
Investor FAQ
Does SAB Biotherapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is SAB Biotherapeutics Inc. Common Stock?
SAB Biotherapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 13, 2026. The company currently has a trailing EPS of -1.29.
Company Profile
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
| Split Date | Split Ratio to 1 |
|---|---|
| Jan. 5, 2024 | 1:10 |
Community Discussion